Research summaries for everyoneNot medical advice
Retatrutide research reference vial, Elevated Pharma

Research reference · Weight & Metabolism

Retatrutide

Retatrutide is an investigational peptide studied at the GLP-1, GIP and glucagon receptors. Phase 3 trials have been reporting since May 2026, and the sponsor plans to file for FDA approval in early 2027.

Published by Elevated Pharma ·

Weight & MetabolismPhase 3 clinical research

Identity

What is Retatrutide?

An investigational triple-receptor agonist (development code LY3437943) that activates GIP, GLP-1 and glucagon receptors.

Research context

What has Retatrutide been studied for?

Published phase 3 trials now include TRIUMPH-1 (NEJM, 2026), TRIUMPH-2 and TRANSCEND-T2D-1 (Lancet, 2026), alongside the 2023 phase 2 trial. Sponsor-reported results add TRIUMPH-3, TRIUMPH-4 and a head-to-head comparison with semaglutide.

Evidence boundary

What does the research not show?

Trial results describe the sponsor’s investigational drug in the studied populations. They do not establish the identity, quality or safety of any independently sourced material.

U.S. status · November 7, 2026

Is Retatrutide FDA-approved?

Investigational. Lilly states retatrutide is legally available only to participants in its clinical trials and plans to submit it for FDA review in the first quarter of 2027.

Research updates

What’s new

Dated developments for Retatrutide, newest first. See all research updates.

  1. TRIUMPH-4 at ACR Convergence

    Lilly presents the 68-week phase 3 TRIUMPH-4 trial in knee osteoarthritis pain as a plenary; knee data from TRIUMPH-1 follow on November 10.

    Read the source
  2. First head-to-head phase 3

    Sponsor-reported TRANSCEND-T2D-2 results compare retatrutide with semaglutide 2 mg in type 2 diabetes over 80 weeks. Full results are not yet published.

    Read the source
  3. TRIUMPH-1 and TRIUMPH-2 published

    TRIUMPH-1 appeared in NEJM and TRIUMPH-2 in The Lancet.

    Read the source
  4. TRIUMPH-2 and TRIUMPH-3 topline

    Lilly reported topline results and said it plans to submit to FDA in Q1 2027.

    Read the source

Key studies

The main Retatrutide research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 216 PubMed records for Retatrutide · Counts and selections checked November 7, 2026.

Reference identifiers

Retatrutide identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
Retatrutide
Also indexed as
LY3437943

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.